We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




World's First Sensor-Enabled Ablation Catheter Designed to Treat Atrial Fibrillation

By HospiMedica International staff writers
Posted on 22 May 2023

Atrial fibrillation (AFib), the most common irregular heart rhythm condition, impacts over 37 million people worldwide, a figure projected to more than double by 2050. More...

With an additional five million cases diagnosed annually, this escalating health concern creates the need for innovative solutions for patients as well as their healthcare providers. Now, a first-of-its-kind ablation catheter designed with a unique flexible electrode tip and contact force sensing, promises shorter procedure times and improved safety for AFib treatment.

Abbott’s (Abbott Park, IL, USA) TactiFlex Ablation Catheter, Sensor Enabled, is the world's first ablation catheter with a flexible tip and contact force technology. The TactiFlex catheter is designed for use with Abbott's EnSite X EP heart mapping system, allowing physicians to view and precisely pinpoint the heart areas requiring ablation. The use of the TactiFlex catheter with the EnSite X EP System enhances visualization for physicians, thereby allowing for higher accuracy and precision, leading to safer and shorter procedures.

In contrast to other catheters available in the market, the TactiFlex catheter utilizes a laser-cut pattern tip design that flexes upon contact with the heart wall. This aids in directing fluid to the treated tissue and ensures more precise catheter positioning – providing stability that's up to twice as high in a beating heart – for consistent therapy delivery. The Abbott TactiFlex catheter demonstrated robust clinical outcomes in the TactiFlex AF IDE study, creating rapid, safe lesions to treat AFib with an acute procedural success rate surpassing 99%. The TactiFlex catheter has been granted approval for usage in Europe, Japan, Africa, and Australia, and has now also received clearance from the U.S. Food and Drug Administration (FDA).

"Abbott is leading the way in helping doctors manage common arrhythmias with the most holistic portfolio for this condition in the world," said Christopher Piorkowski, M.D., chief medical officer of Abbott's electrophysiology business. "The EnSite X EP System is unmatched in determining the exact location where ablation is required. Coupled with the TactiFlex catheter, patients can now feel even more confident that their procedure will deliver safe and effective results."

Related Links:
Abbott 


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Digital Color Doppler Ultrasound System
MS22Plus
LED Surgical Lamp
ACEMST35/57
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: A smartphone application displays a glucose concentration that was measured using the new sensor (Photo courtesy of Chuchu Chen and Yonghao Fu)

Wearable Device for Diabetics Could Replace Continuous Glucose Monitoring Systems

Monitoring blood glucose is essential for people with diabetes to prevent complications and maintain long-term health. Current continuous glucose monitoring systems require needles inserted under the skin,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.